News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,286 Results
Type
Article (41330)
Company Profile (265)
Press Release (688674)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204850)
Career Advice (2032)
Deals (35583)
Drug Delivery (128)
Drug Development (81507)
Employer Resources (173)
FDA (16503)
Job Trends (14981)
News (346817)
Policy (32752)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (46)
Adcomms (26)
Allergies (170)
Alliances (49585)
ALS (210)
Alzheimer's disease (1782)
Antibody-drug conjugate (ADC) (440)
Approvals (16876)
Artificial intelligence (653)
Autoimmune disease (281)
Automation (54)
Bankruptcy (362)
Best Places to Work (11637)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (743)
Cancer (5756)
Cardiovascular disease (466)
Career advice (1724)
Career pathing (42)
CAR-T (328)
CDC (56)
Celiac Disease (3)
Cell therapy (885)
Cervical cancer (47)
Clinical research (70736)
Collaboration (2033)
Company closure (5)
Compensation (1383)
Complete response letters (78)
COVID-19 (2740)
CRISPR (107)
C-suite (1106)
Cystic fibrosis (151)
Data (7767)
Decentralized trials (3)
Denatured (27)
Depression (159)
Dermatology (83)
Diabetes (584)
Diagnostics (6916)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (314)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91940)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119372)
Executive appointments (1075)
FDA (20192)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1704)
Gene editing (232)
Generative AI (55)
Gene therapy (712)
GLP-1 (1049)
Government (4728)
Grass and pollen (6)
Guidances (408)
Healthcare (18994)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (285)
Immuno-oncology (91)
Indications (189)
Infectious disease (3077)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16666)
IRA (50)
Job creations (3647)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (561)
Leadership (39)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (757)
Lymphoma (428)
Machine learning (59)
Management (59)
Manufacturing (1029)
MASH (183)
Medical device (13919)
Medtech (14037)
Mergers & acquisitions (20156)
Metabolic disorders (1486)
mRNA (203)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (411)
Neuropsychiatric disorders (105)
Neuroscience (3278)
Neurotech (1)
NextGen: Class of 2026 (6525)
Non-profit (4530)
Now hiring (77)
Obesity (696)
Opinion (286)
Ovarian cancer (218)
Pain (250)
Pancreatic cancer (294)
Parkinson's disease (356)
Partnered (33)
Patents (592)
Patient recruitment (665)
Peanut (62)
People (59543)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22048)
Phase 2 (31162)
Phase 3 (23191)
Pipeline (8493)
Policy (313)
Postmarket research (2568)
Preclinical (9393)
Press Release (64)
Prostate cancer (293)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1065)
Real estate (5971)
Recruiting (70)
Regulatory (25359)
Reports (56)
Research institute (2414)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (286)
Series B (211)
Service/supplier (11)
Sickle cell disease (111)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3638)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1088)
Venture capital (107)
Weight loss (448)
Women's health (124)
Worklife (20)
Date
Today (225)
Last 7 days (932)
Last 30 days (3476)
Last 365 days (30248)
2026 (11987)
2025 (30170)
2024 (35212)
2023 (40072)
2022 (51174)
2021 (55708)
2020 (54083)
2019 (46544)
2018 (35023)
2017 (32108)
2016 (31480)
2015 (37555)
2014 (31324)
2013 (26351)
2012 (28575)
2011 (29263)
2010 (27330)
Location
Africa (741)
Alabama (92)
Alaska (7)
Arizona (347)
Arkansas (14)
Asia (39650)
Australia (6500)
California (13149)
Canada (3728)
China (1326)
Colorado (565)
Connecticut (571)
Delaware (401)
Europe (85789)
Florida (1964)
Georgia (420)
Hawaii (3)
Idaho (62)
Illinois (1045)
India (88)
Indiana (597)
Iowa (23)
Japan (529)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1578)
Massachusetts (9376)
Michigan (359)
Minnesota (711)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3455)
New Mexico (29)
New York (3434)
North Carolina (1665)
North Dakota (9)
Northern California (6585)
Ohio (393)
Oklahoma (23)
Oregon (41)
Pennsylvania (2641)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5185)
Tennessee (209)
Texas (2084)
United States (46368)
Utah (392)
Vermont (1)
Virginia (316)
Washington D.C. (80)
Washington State (1053)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
730,286 Results for "lakewood amedex inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood
October 13, 2025
·
3 min read
Business
Lakewood-Amedex Appoints Chief Medical Officer and Adds New Management Team Members
Lakewood-Amedex Inc. announced that Sumita Paul, MD, MPH, MBA has joined Lakewood-Amedex as Chief Medical Officer and Senior Vice President, Research and Development to lead its recently recruited scientific-clinical management team.
January 19, 2022
·
4 min read
Drug Development
Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)
Lakewood-Amedex, Inc. announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU).
April 5, 2022
·
4 min read
Press Releases
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
May 5, 2026
·
1 min read
Press Releases
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
February 24, 2025
·
6 min read
Business
LAKEWOOD-AMEDEX APPOINTS TWO NEW BOARD MEMBERS
Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors.
January 25, 2022
·
3 min read
Drug Development
Transparency Life Sciences and Lakewood Amedex Launch Protocol Design for New Clinical Trial on Chronic Diabetic Foot Ulcers
Transparency Life Sciences (TLS) today announced a partnership with the Lakewood Amedex Inc. for crowdsourced design of a Phase 2a/b protocol to test a novel class of synthetic broad-spectrum antimicrobials and antifungals for the treatment of Chronic Diabetic Foot Ulcers (cDFU).
June 3, 2020
·
3 min read
BioMidwest
Lakewood-Amedex Receives Notice of Allowance for Two U.S. Patents Covering the Broad-Spectrum Antimicrobial Nu-8 Bisphosphocin®
Lakewood-Amedex Inc. announced that the U.S. Patent and Trademark Office has issued a “Notice of Allowance” for two broad patent applications related to the Company’s broad-spectrum antimicrobial Nu-8 Bisphosphocin compound, titled “Antimicrobial Compounds, Compositions, and Uses Thereof.” The “Notice of Allowance” indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.
May 27, 2020
·
4 min read
Press Releases
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026
December 4, 2025
·
1 min read
Press Releases
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 13, 2026
·
3 min read
1 of 73,029
Next
